Argenx's Forte Bio Deal Validates CEO Change -- Market Talk
Dow Jones2026/07/28 08:230823 GMT - Argenx's $2.2 billion deal to acquire Forte Biosciences should help the European pharmaceutical company diversify its portfolio and validates a CEO transition that took place earlier this year, Bernstein analysts say in a note. Argenx currently has one successful growth driver, its Vyvgart drug for rare neuromuscular disease myasthenia gravis, but its U.S. patent is due to expire in 2036, the analysts say. The next five years are key for broadening and deepening its pipeline, and the Forte deal helps it lower portfolio-concentration risk, they add. "Moreover, a key reason why [Argenx] underwent its CEO transition in [January] was to try to accelerate complementing its organic pipeline with interesting external assets," Bernstein says. Argenx's shares fall 0.7%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
July 28, 2026 04:23 ET (08:23 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ethereum targets $4,000 as ETF inflows and institutional buying rise
Goldman Sachs: Don't wait for the midterm elections, the "Goldilocks" market may ignite the year-end rally in US stocks ahead of schedule
Goldman Sachs believes that the market has already overestimated the risks of stagflation and high yields. The diminishing effect of tariffs, potential deflation in energy, and cost reductions driven by AI consumerization are expected to push inflation down. Although growth is slowing, core earnings remain strong and central banks have limited room for hawkish moves. In a "Goldilocks" scenario, AI FOMO may be reignited, and there is no need to wait for the midterm elections. The "Goldilocks" rally could trigger a year-end rally in US equities ahead of schedule.
SEC fines OTC Link $575,000 over repeated Regulation SCI compliance failures
Dogecoin Faces 28 Billion DOGE Resistance at $0.098 — Next Wall at $0.11
Crypto prices
More
